piR−34736 |
|
* |
Breast |
Induced by cell cycle progression |
[37] |
piR−36249 |
|
* |
Breast |
Induced by cell cycle progression |
[37] |
piR−35407 |
|
* |
Breast |
Induced by cell cycle progression |
[37] |
piR−36318 |
|
* |
Breast |
Induced by cell cycle progression |
[37] |
piR−34377 |
|
* |
Breast |
Induced by cell cycle progression |
[37] |
piR−36743 |
* |
|
Breast |
Induced by cell cycle progression |
[37] |
piR−36026 |
* |
|
Breast |
Induced by cell cycle progression |
[37] |
piR−31106 |
* |
|
Breast |
Induced by cell cycle progression |
[37] |
piRABC |
|
* |
Bladder |
Increase the expression of TNFSF4 protein |
[38] |
PiR−823 |
|
* |
Gastric |
Inhibit cancer cell growth |
[39] |
piR−55490 |
|
* |
Lung |
Suppress the activation of Akt/mTOR pathway by binding 3/UTR of mTOR messenger RNA and induce its degradation |
[40] |
piR-L−163 |
|
* |
Lung |
Bind directly to phosphorylated ERM protein ) p-ERM) |
[41] |
piR-Hep1 |
* |
|
Liver |
deep sequencing of cell lines, validated in matched tumor-normal tissues via PCR |
[42] |
piR−015551 |
|
* |
Colorectal |
Associated with recurrence-free survival |
[43] |